US-based Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, has announced the inauguration of CoSara Diagnostics's oligonucleotide synthesis facility in Ranoli, Gujarat.

In support of the "Make in India" initiative, the new facility is designed to manufacture the company's patented Co-Primers chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

"We are greatly pleased with the results of this growth stage as we look towards the future, which is expected to include additional facility expansion for manufacturing the Co-Dx PCR Pro instrument and the test cups for illnesses like TB, HPV and more, as we scale to meet the needs of the most populous country in the world," remarked Mohal Sarabhai, CEO of CoSara, the joint venture between Ambalal Sarabhai Enterprises Limited (ASE group) and Co-Diagnostics, Inc. "India is home to some of the world's best and brightest scientists, researchers and medical professionals who we believe will recognise the value of the Co-Primers PCR technology and of the forthcoming testing platform."

Co-Diagnostics' CEO Dwight Egan added, "The new facility and the grantors who helped to fund it provide tangible evidence of the Company's foresight that partnering with Synbiotics Ltd. (an ASE group company) in 2017 to form CoSara would help lay the groundwork for introducing state-of-the-art Co-Dx technology to India's high-tech healthcare marketplace. We believe that synthesising Co-Primers in-house will play a vital role in enhancing manufacturing efficiency and removing barriers as we move towards regulatory approval and commercialisation of our new PCR testing platform in India."